None listed
Conditions
Brief summary
The aim of this study is to evaluate the absorption characteristics of FOUR COENZYME Q10 PRODUCTS. As such this study proposes to evaluate the absorption characteristics of these products by measuring the plasma concentrations following an oral dose. There is significant interest from researchers, general practitioners and the public re: the administration of Coenzyme Q10 supplements for health maintenance or disease treatments such as those with mild to moderate cardiovascular disease, and what differences exist in the absorption characteristics of different formulations.
Interventions
The aim of this study is to evaluate the absorption characteristics of FOUR Coenzyme Q10 PRODUCTS. ONE Coenzyme Q10 preparation will be self administered (orally) on Day 1 of each week. All participants will be allocated the same preparation each day, rotating products each week for 4 weeks. Participants will receive the four products in the order listed below. Allocation: non-randomised, Treatment Endpoint: Characteristics of Coenzyme Q10 in Blood levels, Intervention Model: oro-buccal or oral
The aim of this study is to evaluate the absorption characteristics of FOUR Coenzyme Q10 PRODUCTS. ONE Coenzyme Q10 preparation will be self administered (orally) on Day 1 of each week. All participants will be allocated the same preparation each day, rotating products each week for 4 weeks. Participants will receive the four products in the order listed below. Allocation: non-randomised, Treatment Endpoint: Characteristics of Coenzyme Q10 in Blood levels, Intervention Model: oro-buccal or oral administration, Masking: non-blinded, Primary Purpose: absorption characteristics in blood plasma. Clinical Trial Coordinator to supervise dose administration and any adverse effects. Coenzyme Q10 preparations include: 1) Blackmores CoQ10= 150mg 2) Bioceuticals CoQ10 Liposome= 40mg 3) Bioceuticals Ubiquinol BioActive = 150mg 4) Medlab Clinicals NanoCelle CoQ10= 30mg
Sponsors
Medlab Clinical
Study design
Allocation
Non-randomised trial
Primary purpose
Treatment
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
1) Participants > 18 years of age at time of entry on study 2) Cognitive ability to understand informed consent process and to give informed consent to the experimental treatment 3) Participants agree to undergo venipuncture on multiple occasions or have a catheter inserted 4) Participants agree to adhere to the study protocol 5) No history of any chronic diseases
Exclusion criteria
1) Any clinically relevant abnormal findings which, in the opinion of the investigators / clinicians, may put the participant at risk of adverse events because of participation in the clinical trial including: physical examination, clinical chemistry, haematology, urinalysis, vital signs 2) Any chronic diseases 3) Alcohol abuse 4) Pregnant or nursing an infant 5) Have not been prescribed (medications) or have administered Coenzyme Q10 or any other supplement or vitamin or mineral or herbal medicine in the last week (note: participation will include a 1 week washout period) 6) Any psychiatric disorders by history or examination that would prevent completion of the study or result in possible adverse events for the participant 7) The use of illicit drugs
Outcome results
None listed